+ Site Statistics
References:
54,258,434
Abstracts:
29,560,870
PMIDs:
28,072,757
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries



Access to diagnostics in support of HIV/AIDS and tuberculosis treatment in developing countries



Aids 21(Suppl. 4): S81-S87



Access to necessary diagnostic tests in support of HIV/AIDS and tuberculosis treatment, such as CD4 cell counts, viral load, tuberculosis culture, and susceptibility testing, has significantly lagged the provision of drug therapy in developing countries. This is an outcome of the fundamental limitations in overall access to basic health services in the developing world, particularly in sub-Saharan Africa. Among health services, laboratory capacity and access are particularly deficient, and often non-existent in rural settings. As such, treatment is commonly administered in the absence of diagnostic testing, potentially accelerating the incidence of drug-related toxicity and the onset of drug resistance if therapy results in incomplete viral suppression. Factors constraining the expansion of necessary diagnostic testing include a severe shortage of qualified laboratory personnel, limited access to training for specific diagnostic tests, and a lack of national standards and systems for laboratory accreditation, proficiency testing, quality control and logistics. Additional factors include insufficient funding for improvements in laboratory services, limited availability of technical support, and the cost of diagnostic instrumentation and consumables. As a result, laboratory tests that are routine and expected in the industrialized world are often not performed in developing countries, despite the massive scale-up in treatment access for HIV/AIDS. This results in unintended consequences such as higher levels of mortality among patients who have not been properly diagnosed, additional costs for providing ART to patients who may not yet require drug therapy, and earlier onset of resistance to first-line therapies among patients predisposed to drug resistance.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 014938837

Download citation: RISBibTeXText

PMID: 17620757

DOI: 10.1097/01.aids.0000279710.47298.5c


Related references

Access to treatment for HIV in developing countries; statement from international seminar on access to treatment for HIV in developing countries, London, June 5 and 6, 1998. UK NGO AIDS Consortium Working Group on Access to Treatment for HIV in Developing Countries. Lancet 352(9137): 1379-1380, 1998

Access to treatment for HIV in developing countries Statement from international seminar on access to treatment for HIV in developing countries, London, June 5 and 6, 1998. Lancet (North American Edition) 352(9137): 1379-1380, Oct 24, 1998

Access to AIDS treatment in developing countries: a global issue of equity and human rights. Aids Analysis Asia 4(2): 2-4, 2001

Free care at the point of service delivery: a key component for reaching universal access to HIV/AIDS treatment in developing countries. Aids 22(Suppl. 1): S161-S168, 2008

Progress towards improved tuberculosis diagnostics for developing countries. Lancet 367(9514): 942-943, 2006

Cooperation forms to accelerate access to AIDS care in developing countries. Aids Reader 10(6): 339-339, 2000

Tuberculosis control and the AIDS epidemic in developing countries. Annals of Internal Medicine 113(2): 89-91, 1990

UNAIDS expands HIV drug access in developing countries. Joint United Nations Programme on HIV/AIDS. Nature Medicine 3(12): 1307, 1997

Urgent need for a new approach to the diagnosis of tuberculosis in developing countries in the decade of AIDS. Tropical and Geographical Medicine 45(4): 145-149, 1993

Tuberculosis and atypical mycobacterioses in aids patients from developing and developed countries. American Review of Respiratory Disease 141(4 PART 2): A261, 1990

The potential impact of AIDS on the tuberculosis situation in developed and developing countries. Bulletin of the International Union Against Tuberculosis and Lung Disease 63(2): 25-28, 1988

The Developing Countries Vaccine Manufacturers' Network (DCVMN) is a critical constituency to ensure access to vaccines in developing countries. Vaccine 26(13): 1611-1615, 2008

Evaluating the Usefulness of Compulsory Licensing in Developing Countries: A Comparative Study of Thai and Brazilian Experiences Regarding Access to Aids Treatments. Developing World Bioethics 17(2): 90-99, 2016

Possible effects of acquired immunologic deficiency syndrome (AIDS) on tuberculosis in industrial and developing countries. Pneumologie 44(Suppl. 1): 647-652, 1990

Access to treatment for HIV in developing countries. Lancet 353(9147): 153, 1999